A Study of LY3502970 in Participants With Normal and Impaired Renal Function
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment
Sponsor: Eli Lilly and Company
Listed as NCT05936138, this PHASE1 trial focuses on Healthy and Renal Insufficiency and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Mar 2024 — May 2024 [monthly]
Recruiting PHASE1
Status: Completed → Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Nov 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jul 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .